CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.…
CG Oncology’s CEO Called Its Trial Results a “Defining Milestone.” Then He and Another Executive Bought $2.7 Million of Stock
CG Oncology (NASDAQ: CGON) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 142 employees.
The shares were at 79.47 USD on 20 November 2026, up 100.3% over 52 weeks. Its 52-week range is 35.80 USD to 93.95 USD: the price is 15.4% below the high and 122.0% above the low.
Its market capitalisation is 7.10B USD.
CG Oncology reports return on equity of -21.4% and revenue down 3.7% year over year.
It holds more cash than debt, a net cash position of 975.22M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 109.69 USD is 38.0% above the current price. The next earnings report is expected on 26 February 2027.